Total Body Irradiation
Phase 2Small molecule
Total Body Irradiation is one of 83 small molecule programs targeting Sickle Cell Disease. It is currently in Phase 2.
3
Indications
7
Total Trials
4
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in Sickle Cell Disease
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Phase 3
Ritalin
NovartisPhase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Fludara
SanofiPhase 2
Cellcept
RochePhase 2
Aqvesme
AAgios Pharmaceuticals, Inc.
Phase 3
PIASKY
RochePhase 3
Tepadina
Jazz PharmaceuticalsPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Orencia
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Stem Cell Transplantation1 trial
Donor Stem Cell Transplantation for Congenital Immunodeficiencies
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00426517·48 enrolled
Malignancy1 trial
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled
Sickle Cell Disease1 trial
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
Recruiting·—·Phase 1·NCT07015684·24 enrolled
2 more indications
Bone Marrow Transplantation1 trial
Chronic Granulomatous Disease1 trial
Phase I/II Study Using Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT05463133·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Total Body Irradiation. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details